Neurologist writes "explosion of new and innovative" therapies for neurologic conditions

There has been an "explosion of new and innovative" therapies for neurologic conditions such as stroke, epilepsy, Parkinson disease and multiple sclerosis, Loyola University Medical Center neurologist Dr. Jose Biller writes in the August issue of the journal Neurologic Clinics.

Biller is editor of the August issue, which includes 14 articles describing the latest data on new and emerging therapies for neurologic conditions. Five of the articles are written by Loyola physicians:

Sarkis Morales Vidal, MD and Sean Ruland, DO: "Platelet Antiaggregants in Stroke Prevention."

Adriana Sofia Ploneda Perilla and Michael J. Schneck, MD: "Unanswered Questions in Thrombolytic Therapy for Acute Ischemic Stroke."

Michael Star, MD and Murray Flaster, MD, PhD: "Advances and Controversies in the Management of Cerebral Venous Thrombosis."

Jorge J. Asconape: "Epilepsy."

Douglas Anderson, MD and Ninith Kartha, MD: "Deep Brain Stimulation in Nonparkinsonian Movement Disorders and Emerging Technologies, Targets and Therapeutic Promises in Deep Brain Stimulation."

Matthew McCoyd, MD: "Update on Therapeutic Options for Multiple Sclerosis."

In the preface, Biller writes that the August issue of Neurologic Clinics is intended to provide timely and practical information to physicians treating neurologic disorders. He concludes: "There is every reason to believe that future advances in neurologic therapy are sure to come."

Source: Loyola University Chicago Stritch School of Medicine

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Anxiety and negative emotions reduced by brain circuit that consciously slows breathing